236 TWELVE-WEEK COURSE OF PIFN-α-2A/RIBAVIRIN IS AN OPTIMIZED REGIMEN FOR TREATMENT OF HCV GENOTYPE 2 BUT NOT GENOTYPE 3 NON-CIRRHOTIC PATIENTS WITH RVR

Authors :: Maria Giovanna Ferrara
Rosa Zampino
Luigi Elio Adinolfi
Luciano Restivo
Luca Rinaldi
Giuseppe Ruggiero
A. Ciervo
V.R. Scialdone
Barbara Guerrera
Source :: Journal of Hepatology. 52:S99-S100
Publication Year :: 2010
Publisher :: Elsevier BV, 2010.

Subjects :: Regimen
chemistry.chemical_compound
medicine.medical_specialty
Hepatology
chemistry
business.industry
Ribavirin
Internal medicine
Genotype
medicine
business
Gastroenterology

Full Text Access

Tools